ECSP13012913A - Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) - Google Patents

Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Info

Publication number
ECSP13012913A
ECSP13012913A ECSP13012913A ECSP13012913A EC SP13012913 A ECSP13012913 A EC SP13012913A EC SP13012913 A ECSP13012913 A EC SP13012913A EC SP13012913 A ECSP13012913 A EC SP13012913A
Authority
EC
Ecuador
Prior art keywords
tfpi
monoclonal antibodies
inhibitor
antibodies against
tissular
Prior art date
Application number
Other languages
English (en)
Inventor
John E Murphy
Zhuozhi Wang
Tobias Marquardt
Dieter Moosmayer
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of ECSP13012913A publication Critical patent/ECSP13012913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan anticuerpos monoclonales aislados que se unen a epítopos específicos del inhibidor de la ruta del factor tisular humano (TFPI) y las moléculas de ácido nucleico aisladas que los codifican. También se proporcionan composiciones farmacéuticas que comprenden los anticuerpos monoclonales anti-TFPI y procedimientos de tratamiento de deficiencias o defectos en la coagulación por la administración de los anticuerpos.
ECSP13012913 2011-04-01 2013-10-01 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) ECSP13012913A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
ECSP13012913A true ECSP13012913A (es) 2014-02-28

Family

ID=46932389

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012913 ECSP13012913A (es) 2011-04-01 2013-10-01 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Country Status (37)

Country Link
US (5) US20140294832A1 (es)
EP (1) EP2694544B1 (es)
JP (4) JP6170903B2 (es)
KR (2) KR20190079698A (es)
CN (2) CN103797030B (es)
AU (3) AU2012236296A1 (es)
BR (1) BR112013025376A2 (es)
CA (2) CA3068997A1 (es)
CL (1) CL2013002811A1 (es)
CO (1) CO6890074A2 (es)
CR (1) CR20130499A (es)
CU (1) CU20130128A7 (es)
CY (1) CY1121538T1 (es)
DK (1) DK2694544T3 (es)
DO (1) DOP2013000218A (es)
EA (2) EA201991704A3 (es)
EC (1) ECSP13012913A (es)
ES (1) ES2722824T3 (es)
GT (1) GT201300229A (es)
HK (1) HK1243426A1 (es)
HR (1) HRP20190467T1 (es)
HU (1) HUE042706T2 (es)
IL (4) IL228633B (es)
LT (1) LT2694544T (es)
MX (1) MX2013011218A (es)
MY (2) MY165499A (es)
PE (1) PE20141149A1 (es)
PH (4) PH12013502039B1 (es)
PL (1) PL2694544T3 (es)
PT (1) PT2694544T (es)
RS (1) RS58633B1 (es)
SG (2) SG193594A1 (es)
SI (1) SI2694544T1 (es)
TR (1) TR201905101T4 (es)
UA (1) UA113623C2 (es)
WO (1) WO2012135671A2 (es)
ZA (1) ZA201308169B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ607892A (en) 2008-12-19 2014-11-28 Baxter Int Tfpi inhibitors and methods of use
DK2379600T4 (da) † 2008-12-22 2021-01-04 Novo Nordisk As Antistoffer mod tissue factor pathway inhibitor
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
EP2547355B1 (en) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
HUE042706T2 (hu) * 2011-04-01 2019-07-29 Bayer Healthcare Llc Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen
NZ629130A (en) * 2012-03-21 2016-10-28 Baxalta Inc Tfpi inhibitors and methods of use
CN104185474B (zh) * 2012-03-30 2017-08-25 拜尔健康护理有限责任公司 蛋白酶调节的抗体
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CA2906128A1 (en) 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
EP2970499B1 (en) * 2013-03-15 2022-08-10 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
WO2015007880A1 (en) * 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
EP3262075B1 (en) * 2015-02-25 2024-03-13 Mogam Institute For Biomedical Research Novel antibody binding to tfpi and composition comprising the same
KR102068915B1 (ko) * 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
US20210263052A1 (en) * 2018-07-25 2021-08-26 Sony Corporation Blood coagulation system analysis device
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
DK2379600T4 (da) * 2008-12-22 2021-01-04 Novo Nordisk As Antistoffer mod tissue factor pathway inhibitor
USRE47150E1 (en) * 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
HUE042706T2 (hu) * 2011-04-01 2019-07-29 Bayer Healthcare Llc Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Also Published As

Publication number Publication date
IL283829A (en) 2021-07-29
IL228633B (en) 2018-03-29
EP2694544A4 (en) 2015-03-25
EP2694544A2 (en) 2014-02-12
MX2013011218A (es) 2013-10-17
ES2722824T3 (es) 2019-08-19
US20220041752A1 (en) 2022-02-10
RS58633B1 (sr) 2019-05-31
EA201991704A2 (ru) 2020-03-31
DK2694544T3 (en) 2019-04-15
NZ615969A (en) 2016-01-29
MY165499A (en) 2018-03-27
PE20141149A1 (es) 2014-08-28
EA201301107A1 (ru) 2014-11-28
PL2694544T3 (pl) 2019-07-31
SG10201602606UA (en) 2016-04-28
WO2012135671A3 (en) 2012-12-13
PH12019500439A1 (en) 2020-10-12
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
EP2694544B1 (en) 2019-01-23
CY1121538T1 (el) 2020-05-29
IL257145A (en) 2018-03-29
HUE042706T2 (hu) 2019-07-29
UA113623C2 (uk) 2017-02-27
SG193594A1 (en) 2013-10-30
KR20140019428A (ko) 2014-02-14
GT201300229A (es) 2014-11-13
CN103797030B (zh) 2017-05-31
CR20130499A (es) 2013-10-24
JP2014511685A (ja) 2014-05-19
CA2831907C (en) 2020-03-24
HK1243426A1 (zh) 2018-07-13
DOP2013000218A (es) 2013-11-15
WO2012135671A2 (en) 2012-10-04
AU2017203105A1 (en) 2017-06-01
CL2013002811A1 (es) 2014-02-28
IL228633A0 (en) 2013-12-31
US20170107298A1 (en) 2017-04-20
JP2017113019A (ja) 2017-06-29
JP2021019619A (ja) 2021-02-18
AU2012236296A1 (en) 2013-10-24
BR112013025376A2 (pt) 2017-07-25
US20190194353A1 (en) 2019-06-27
EA034214B1 (ru) 2020-01-17
PH12013502039A1 (en) 2013-12-16
SI2694544T1 (sl) 2019-06-28
CN107090046A (zh) 2017-08-25
US20140294832A1 (en) 2014-10-02
US20180194857A1 (en) 2018-07-12
JP6363747B2 (ja) 2018-07-25
PH12013502039B1 (en) 2013-12-16
KR101995302B1 (ko) 2019-07-02
JP6170903B2 (ja) 2017-07-26
CO6890074A2 (es) 2014-03-10
ZA201308169B (en) 2016-03-30
AU2019201814A1 (en) 2019-04-04
JP2018172411A (ja) 2018-11-08
IL274686A (en) 2020-06-30
IL274686B (en) 2021-09-30
PT2694544T (pt) 2019-04-02
CN103797030A (zh) 2014-05-14
CA2831907A1 (en) 2012-10-04
CU20130128A7 (es) 2014-03-26
HRP20190467T1 (hr) 2019-05-03
EA201991704A3 (ru) 2020-06-30
PH12019500441A1 (en) 2020-10-12
LT2694544T (lt) 2019-04-25
TR201905101T4 (tr) 2019-05-21
CA3068997A1 (en) 2012-10-04
KR20190079698A (ko) 2019-07-05

Similar Documents

Publication Publication Date Title
ECSP13012913A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
ECSP12012134A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
ECSP11010810A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CR20130624A (es) Proteínas de unión a antígeno
CU24498B1 (es) Anticuerpos de factor xi
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
UY33575A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CY1118254T1 (el) Αντισωματα toy βμρ-6
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
BR112013027851A2 (pt) métodos para identificar um indivíduo caucasiano e para determinar uma suscetibilidade do indivíduo caucasiano de ter ou desenvolver a degeneração macular relacionada com a idade, e, kit
TH149802A (th) โปรตีนจับเกาะแอนติเจน